Caldera Humberto, Giralt Sergio
Department of Blood and Marrow Transplantation, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Curr Hematol Rep. 2004 Jul;3(4):249-56.
High-dose chemotherapy or chemoradiation therapy supported with autologous stem cell transplantation is now recognized as a valid therapeutic option for patients with multiple myeloma. Results of randomized trials have established autografting as the treatment of choice for patients younger than 65 years, as part of their initial therapy. In this review, the issues of who benefits from transplant, what is the optimal procedure, and whether there is a potential role for allografting are addressed.
高剂量化疗或联合自体干细胞移植的放化疗，目前被公认为是多发性骨髓瘤患者的一种有效治疗选择。随机试验结果已确立自体移植作为65岁以下患者初始治疗一部分的首选治疗方法。在本综述中，探讨了哪些患者能从移植中获益、最佳治疗程序是什么以及同种异体移植是否具有潜在作用等问题。
